Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Berk

Showing results (291-300 of 398) with videos related to

Pageof 40
Sort By:
Haematologica|June 27, 2012
Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experienceAndrew J Cowan, Martha Skinner, David C Seldin, et al.
American Journal of Physiology. Cell Physiology|June 11, 2002
NF-kappaB induced by IL-1beta inhibits elastin transcription and myofibroblast phenotypePing-Ping Kuang, John L Berk, David C Rishikof, et al.
Annals of Internal Medicine|May 1, 2001
Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal diseaseL M Dember, V Sanchorawala, D C Seldin, et al.
Journal of Racial and Ethnic Health Disparities|October 20, 2025
The Influence of Mistrust, Communication, and Advocacy on Black Women's Pregnancy-Related Healthcare DecisionsNatalie A Axelrod, Nicole C Hammer, Abigail L Berk, et al.
Antiviral Research|June 1, 1993
Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infectionR A Heijtink, G A De Wilde, J Kruining, et al.
Comprehensive Psychiatry|June 26, 2014
Quality of life in bipolar and schizoaffective disorder--a naturalistic approachM Martín-Subero, L Berk, S Dodd, et al.
British Journal of Haematology|June 13, 2002
Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosisVaishali Sanchorawala, Daniel G Wright, David C Seldin, et al.
Neurology and Therapy|March 21, 2024
Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A StudyMarco Luigetti, Dianna Quan, John L Berk, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|November 29, 2022
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchangeFelix J Tsai, Luke T Nelson, Gabriel M Kline, et al.
Digestive Diseases and Sciences|November 21, 2001
Tumor necrosis factor-alpha, interleukin-6, and nitric oxide in sterile ascitic fluid and serum from patients with cirrhosis who subsequently develop ascitic fluid infectionJ Such, D J Hillebrand, C Guarner, et al.
Pageof 40

Showing results (291-300 of 398) with videos related to

Sort By:
Pageof 40
Haematologica|June 27, 2012
Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experienceAndrew J Cowan, Martha Skinner, David C Seldin, et al.
American Journal of Physiology. Cell Physiology|June 11, 2002
NF-kappaB induced by IL-1beta inhibits elastin transcription and myofibroblast phenotypePing-Ping Kuang, John L Berk, David C Rishikof, et al.
Annals of Internal Medicine|May 1, 2001
Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal diseaseL M Dember, V Sanchorawala, D C Seldin, et al.
Journal of Racial and Ethnic Health Disparities|October 20, 2025
The Influence of Mistrust, Communication, and Advocacy on Black Women's Pregnancy-Related Healthcare DecisionsNatalie A Axelrod, Nicole C Hammer, Abigail L Berk, et al.
Antiviral Research|June 1, 1993
Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infectionR A Heijtink, G A De Wilde, J Kruining, et al.
Comprehensive Psychiatry|June 26, 2014
Quality of life in bipolar and schizoaffective disorder--a naturalistic approachM Martín-Subero, L Berk, S Dodd, et al.
British Journal of Haematology|June 13, 2002
Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosisVaishali Sanchorawala, Daniel G Wright, David C Seldin, et al.
Neurology and Therapy|March 21, 2024
Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A StudyMarco Luigetti, Dianna Quan, John L Berk, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|November 29, 2022
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchangeFelix J Tsai, Luke T Nelson, Gabriel M Kline, et al.
Digestive Diseases and Sciences|November 21, 2001
Tumor necrosis factor-alpha, interleukin-6, and nitric oxide in sterile ascitic fluid and serum from patients with cirrhosis who subsequently develop ascitic fluid infectionJ Such, D J Hillebrand, C Guarner, et al.
Pageof 40